Medical/Pharmaceuticals
BrainCo Helps Amputee Showcase Technology at WAIC 2025
BOSTON, Sept. 8, 2025 /PRNewswire/ -- At the 2025 World Artificial Intelligence Conference (WAIC) inAugust 2025, Gu demonstrated the BrainCo Intelligent Bionic Hand. He played the piano with precision and even explained to attendees how brain-computer interface (BCI) technology enables amputees t...
2025-09-08 19:29
1059
Remplir™ Study Delivers Compelling 81% Success Rate
Data to support US sales roll out and EU + UK regulatory submissions * Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. * Real World Evidence (RWE) patient data collected in the study confirms Ortho...
2025-09-08 17:32
1451
Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines
HONG KONG, Sept. 7, 2025 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a stra...
2025-09-08 12:15
1087
Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
SHANGHAI, Sept. 7, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a$60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Pa...
2025-09-08 10:00
1233
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
* The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 * In the North American patients, the OS HR was 0.70 * The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) ...
2025-09-07 18:08
1701
Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase1b/2 clin...
2025-09-05 16:46
1363
Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights...
2025-09-05 16:09
1598
Alma, a Sisram Medical Company, Announces Strategic Collaboration with Celebrity Skin Expert Nurse Jamie to Expand Global Consumer Presence
HONG KONG, Sept. 4, 2025 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions, today announced a strategic collaboration between its subsidiary Alma, a global leader in energy-based medical and aesthetic solutions, andJamie Sher...
2025-09-04 22:00
1610
Global Bio Conference 2025 kicks off in Seoul, charting biotech's future
SEOUL, South Korea, Sept. 3, 2025 /PRNewswire/ -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety announced Wednesday that it kicked off Global Bio Conference 2025, under the theme "Bio, Navigating Infinite Possibilities." The conference will be held from...
2025-09-03 20:00
1601
Acer Expands SpatialLabs Pro Ecosystem with Immersive 3D Capabilities Across Multiple Verticals
Editor's Summary * Integration with NVIDIA Omniverse libraries via OpenXR runtime supports enhanced spatial awareness for industrial designs and simulations * Partnership with Video Engineering brings 3D stereo microscopy to inspection, design, and prototyping workflows * Collaboration with...
2025-09-03 17:40
1470
Acer Medical Unveils aiMed Ahead of IFA 2025, Showcasing the Future of AI in Healthcare
BERLIN, Sept. 3, 2025 /PRNewswire/ -- Acer Medical, an Acer Group company specializing in medical imaging and AI-powered healthcare solutions, unveiled aiMed, its next-generation generative AI medical documentation system at the next@acer global press conference, ahead ofIFA 2025 in Berlin. The mi...
2025-09-03 17:30
1712
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment ofJason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developin...
2025-09-03 10:52
1635
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data
* Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data * Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet...
2025-09-02 21:00
2187
Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions h...
2025-09-02 21:00
1928
Desilo to Launch "HARVEST™," Encrypted Data Collaboration Platform for Healthcare, in December
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform,HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical c...
2025-09-02 21:00
1810
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...
2025-09-02 20:30
3584
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...
2025-09-02 19:00
1615
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 /PRNe...
2025-09-02 18:00
1358
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
2025-09-02 17:52
1261
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...
2025-09-02 16:00
1322
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4866
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3965
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3881
Dreame Technology Recognized on Fast Company's List of Brands That Matter
2025-12-06 01:30
3379
Cyient Semiconductors Qualifies for Key Bid in Semi-Conductor Laboratory-Mohali Revamp
2025-12-06 02:00
2588